Press Releases
June 2, 2011
ACT Biotech’s Telatinib Demonstrates Significant Progress in Stomach Cancer Treatment; Phase 2 Data To Be Presented at ASCO. FDA Agrees on SPA for Phase 3 Combination Trial in Stomach Cancer
ACT BIOTECH announced positive data from the Phase 2 clinical trial evaluating the novel oral antiangiogenic agent telatinib in combination with standard-of-care chemotherapy regimen as first-line treatment for patients with metastatic stomach cancer, the second most deadly tumor type in the world. The trial was conducted in multiple centers in the U.S. and Spain. These data will be presented at the eighth annual American Society of Clinical Oncology annual meeting that will take place June 3-6, 2011, in Chicago, IL.
Read the story (PDF, 119K) >
May 19, 2011
ACT BIOTECH to Present Significant Progress in Stomach Cancer Treatment at
ASCO
ACT BIOTECH, Inc today announced that it will present encouraging results on the telatinib Phase 2 clinical trial in patients with advanced stomach cancer. Data from the front-line treatment study will be presented at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting taking place June 3 through June 7, 2011, in Chicago, Illinois. Read the story (PDF, 90K) >
February 28, 2011
ACT Biotech Files Special Protocol Assessment With FDA for Phase 3 Trial of Telatinib for Front-Line Treatment of Stomach Cancer
ACT Biotech, Inc., a biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of cancer, announced today that it has filed a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) related to a randomized Phase 3 trial of telatinib in combination with chemotherapy for the first-line treatment of patients with advanced stomach cancer. Read the story (PDF, 78K) >
January 20, 2011
Phase 2 Data in Stomach Cancer Show Telatinib’s Potent Antiangiogenic Activity
ACT Biotech, Inc., a biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of cancer, today released data on additional analysis of the Phase 2 clinical trial of telatinib in patients with metastatic stomach cancer that further supports the highly potent nature of the antiangiogenic agent. These data were presented at the eighth annual ASCO 2011 Gastrointestinal Cancer Symposium that is taking place on January 20-22, 2011, in San Francisco, CA. Read the story (PDF, 147K) >
November 18th, 2010
ACT BIOTECH Broadens Pipeline with Advance of Two New Cancer Drugs
ACT Biotech Inc., a privately held biotechnology company based in San Francisco, California, yesterday presented new data from two late pre-clinical cancer drug candidates, further broadening their pipeline of targeted cancer therapeutics. Read the story (PDF, 66K) >
October 11, 2010
ACT BIOTECH Announces Positive Interim Phase 2 Results with Telatinib in First-line Gastric Cancer
ACT Biotech Inc., a privately held biotechnology company based in San Francisco, California, today announced positive interim data from a Phase 2 trial of the Company’s lead oral kinase inhibitor, Telatinib, for the first-line treatment of patients with advanced gastric cancer. This proof-of-concept, multi-center, open label trial was designed to test the efficacy and safety of full-dose Telatinib, administered continuously, as a first-line treatment in combination with a standard regimen of capecitabine and cisplatin in US and European patients. Read the story (PDF, 16K) >
June 2, 2010
ACT BIOTECH Receives Orphan Drug Designation for Telatinib, an Orally Available and Highly Selective Kinase Inhibitor, in Gastric Cancer
ACT Biotech Inc., a privately held biotechnology company developing a portfolio of oral kinase inhibitors as anti-cancer drugs, announced today that the company’s highly selective oral kinase inhibitor, Telatinib, has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of gastric cancer. Telatinib is currently in Phase 2 clinical testing in the United States and in Europe for the first-line treatment of advanced gastric cancer patients in combination with standard-of-care chemotherapy. Read the story (PDF, 16K) >
January 22, 2010
ACT BIOTECH Announces FDA Acceptance of IND for ACTB1003, a First-in-Class Anti-Cancer Therapeutic
July 30, 2009
ACT Biotech announces treatment of first gastric cancer patients with Telatinib in a Phase 2 clinical trial in the US and Spain
ACT In the News
May 13, 2011
BioWorld Today - Living Up to its Acronym, ACT Nears Telatinib Phase III
The “ACT” in ACT Biotech Inc. stands for “accelerate cancer therapeutics” and the 3-year-old San Francisco based company is living up to its acronym as it nears the start of a Phase III trial in the second half of this year of lead candidate telatinib in combination with chemotherapy Read the story (PDF, 53K) >
May 9, 2011
BioCentury - Emerging Compamy profile: ACTing Selectively
ACT Biotech Inc. is a new pharmaceutical company with a focus on oral kinase inhibitors for the treatment of cancer, but it has its roots in one of pharma’s oldest players. Read the story (PDF, 66K) >
April, 2011
Start-Up - ACT Biotech Inc.: Oral kinase inhibitors for cancer
ACT Biotech Inc. believes the selectivity of its telatinib will allow it to be combined with full-dose chemotherapy in a variety of solid tumor types. Read the story (PDF, 332K) >
Events
May 24-26, 2011
13th Annual C21BioVentures
The 13th annual conference in Napa, California. More information >
June 3-7, 2011
2011 ASCO Chicago
The 47th annual ASCO meeting. More information >
January 20-22, 2011
2011 ASCO GI
The Gastrointestinal Cancers Symposium is a three-day scientific and educational meeting on new advances in the prevention, screening and treatment of gastrointestinal cancers. More information >
November 16-19, 2010
22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Hosted by EORTC, NCI and AACR, the 2010 symposium, ‘Molecular Targets and Cancer Therapeutics’ brought together academics, scientists and representatives from the pharmaceutical industry to discuss innovation in drug development, target selection and the impact of new discoveries in molecular and cell biology. More information >
October 8-12, 2010
2010 Congress of ESMO, the European Society of Medical Oncology
The European Society for Medical Oncology (ESMO) is the leading European professional organization, committed to advancing the specialty of medical oncology and promoting a multidisciplinary approach to cancer treatment and care. More information >
June 4-8, 2010
American Society for Clinical Oncology (ASCO) annual meeting 2010, Chicago, Illinois
The 2010 ASCO Annual Meeting will focus on Advancing Quality through Innovation. Join your colleagues from around the world and participate in discussions on the latest innovations in research, quality, practice, and technology in cancer. More information >